Iridex Corp. earnings were relatively stable and revenue climbed 15 percent in the second quarter as the company continues to promote its laser eye treatment product. Revenues were $10.6 million, compared to $9.2 million in the second quarter of 2013. Net income was $300,000, compared to net income in last year's second quarter of $400,000. The company expects revenue of $10 million to $10.3 million, representing growth of 5 percent to 8 percent over last year’s third quarter. Iridex CEO Will Moore said sales were strong for MicroPulse, a laser system for treating diabetes-related retinal disease. The results from a one-year, multicenter study of MicroPulse technology as a treatment for glaucoma were presented at the American Society of Cataract and Refractive Surgeons conference in April. Meanwhile, Iridex’s board of directors recently established a new $3 million share repurchase program, following on another that involved buying approximately 377,000 shares at an average price of $7.97 since February 2013. For more information, visit www.iridex.com.